 |
|
Pharmacotherapy for Adolescent Obesity
A Weighty Issue
Alain Joffe, MD, MPH
JAMA. 2005;293:2932-2934.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Until public health efforts to prevent child and adolescent obesity are developed and successfully implemented on a broad scale, physicians are likely to encounter significant numbers of obese adolescents for the foreseeable future. Many of these young people display features associated with the development of type 2 diabetes and cardiovascular disease, and some experience social stigma and other psychosocial morbidity. Research has shown that obese adolescents are likely to become obese adults,1 yet changing the trajectory of obesity in this age group remains an elusive goal. Hence, appropriate management of this chronic health condition is a pressing but daunting task for physicians.
Given this background, any promising intervention is certain to attract considerable attention. Such will be the case with the clinical trial published in this issue of JAMA by Chanoine and colleagues,2 which shows that after a year of treatment, adolescents taking 120 mg of . . . [Full Text of this Article]
Author Affiliation: Student Health and Wellness Center, Johns Hopkins University, Baltimore, Md.
RELATED ARTICLE
Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial
Jean-Pierre Chanoine, Sarah Hampl, Craig Jensen, Mark Boldrin, and Jonathan Hauptman
JAMA. 2005;293(23):2873-2883.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Orlistat and Weight Loss in Adolescents
JWatch General 2005;2005:1-1.
FULL TEXT
|
